Trial Profile

Feasibility Study of Empagliflozin As Treatment for Idiopathic Pulmonary Arterial Hypertension

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 25 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Empagliflozin (Primary)
Indications Pulmonary arterial hypertension
Focus Adverse reactions; Proof of concept
Acronyms Emphower PoC

Most Recent Events

20 Nov 2024 Status changed from recruiting to completed.
18 Nov 2024 Results assessing safety of of EMPA as add-on therapy in eight patients with a prior PAH presented at the American Heart Association Scientific Sessions 2024
02 Mar 2023 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com